Iovance Biotherapeutics (IOVA) KOL event summary

Introduction and agenda

• Event featured a five-year data analysis of a one-time cell therapy for metastatic melanoma, with a KOL panel and executive Q&A session.

• The event included an introduction by the Chief Commercial Officer, product overview, panelist introductions, and discussion of clinical and operational experiences.

KOL background and credentials

• Panel included leading oncologists from University of Chicago, Georgetown University, and Endeavor Health, including Dr. Dan Olson, Dr. Geoffrey Gibney, Dr. Bruce Brockstein, and Dr. Peter Prieto, all with extensive experience in melanoma and cell therapy.

Market insights and analysis

• Over 1,000 patients have been treated with approved therapies, with more than 300 treated commercially and over 80 authorized treatment centers as of May 2025.

• 250M+ patient lives are covered, with most having private insurance, and typical financial clearance takes about three weeks.

• The global advanced melanoma patient treatment opportunity is estimated at over 70,000.

• Strong payer coverage and pending ex-US approvals in the UK, EU, and Canada.